Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Gerds, AT, Savona, MR, Scott, BL, Talpaz, M, Egyed, M, Harrison, CN, Yacoub, A, Vannucchi, A, Mead, AJ, Kiladjian, J-J, O'Sullivan, J, García-Gutiérrez, V, Bose, P, Rampal, RK, Miller, CB, Palmer, J, Oh, ST, Buckley, SA, Mould, DR, Ito, K, Tyavanagimatt, S, Smith, JA, Roman-Torres, K, Devineni, S, Craig, AR, Mascarenhas, JO
Natura:	Journal article
Lingua:	English
Pubblicazione:	American Society of Hematology 2020

Documenti analoghi

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
di: Harrison, C, et al.
Pubblicazione: (2023)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
di: Srdan Verstovsek, et al.
Pubblicazione: (2021-09-01)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
di: Claire Harrison, et al.
Pubblicazione: (2023-01-01)

<i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
di: Srdan Verstovsek, et al.
Pubblicazione: (2024-04-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
di: C. Harrison, et al.
Pubblicazione: (2022-06-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
di: A. Vannucchi, et al.
Pubblicazione: (2022-06-01)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
di: O'Sullivan, JM, et al.
Pubblicazione: (2023)

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
di: Mesa, R, et al.
Pubblicazione: (2017)

P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
di: Jan Bewersdorf, et al.
Pubblicazione: (2023-08-01)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
di: Naveen Pemmaraju, et al.
Pubblicazione: (2022-11-01)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
di: Nico Gagelmann, et al.
Pubblicazione: (2023-08-01)

Low-dose thalidomide in myelofibrosis
di: Robert Weinkove, et al.
Pubblicazione: (2008-07-01)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
di: Lucia Masarova, et al.
Pubblicazione: (2023-08-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
di: Claire Harrison, et al.
Pubblicazione: (2022-08-01)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
di: V. Gupta, et al.
Pubblicazione: (2022-06-01)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
di: Moshe Talpaz, et al.
Pubblicazione: (2018-08-01)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
di: Harrison, C, et al.
Pubblicazione: (2016)

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY
di: G. Tremblay, et al.
Pubblicazione: (2022-06-01)

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
di: Ernesto José Cuenca Zamora, et al.
Pubblicazione: (2023-08-01)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
di: Srdan Verstovsek, et al.
Pubblicazione: (2016-12-01)

Mega-dose methylprednisolone (MDMP) for chronic idiopathic myelofibrosis
di: Şinasi Özsoylu
Pubblicazione: (2010-12-01)

Mega-dose methylprednisolone (MDMP) for chronic idiopathic myelofibrosis
di: Şinasi Özsoylu
Pubblicazione: (2010-12-01)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
di: Marina Kremyanskaya, et al.
Pubblicazione: (2023-08-01)

Profile of pacritinib and its potential in the treatment of hematologic disorders
di: Hatzimichael E, et al.
Pubblicazione: (2014-08-01)

P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS
di: H. Gill, et al.
Pubblicazione: (2022-06-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
di: Verstovsek, S, et al.
Pubblicazione: (2021)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
di: J.-J. Kiladjian, et al.
Pubblicazione: (2022-06-01)

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR
di: S. Verstovsek, et al.
Pubblicazione: (2022-06-01)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
di: Jean-Jacques Kiladjian, et al.
Pubblicazione: (2023-11-01)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
di: Singer J, et al.
Pubblicazione: (2016-08-01)

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES
di: C. Harrison, et al.
Pubblicazione: (2022-06-01)

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
di: A. Vannucchi, et al.
Pubblicazione: (2022-06-01)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
di: Ruben Mesa, et al.
Pubblicazione: (2023-06-01)

Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone
di: Petra Bělohlávková, et al.
Pubblicazione: (2016-08-01)

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
di: J. Mascarenhas, et al.
Pubblicazione: (2022-06-01)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
di: Aaron T. Gerds, et al.
Pubblicazione: (2023-08-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
di: Claire N. Harrison, et al.
Pubblicazione: (2021-05-01)

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
di: Claire Harrison, et al.
Pubblicazione: (2023-08-01)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
di: Al-Fayoumi S, et al.
Pubblicazione: (2018-05-01)

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
di: Alessandro M. Vannucchi, et al.
Pubblicazione: (2019-05-01)